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Utilizing Pharmacology to Target Transcription Factors
Involved with Cancer Onset and Development
Tristan D. Sanders
West Virginia University
Transcription factors (TFs) are a vital part of every living organism on Earth as they allow
for the correct genes to be expressed. However, TFs can fall victim to mutations or
manipulations that lead to the deregulation of many genes within a cell. If specific genes are
over/under-expressed, a cell may become cancerous and begin replicating into a tumor. It has
been demonstrated that common TFs associated with cancer can be targeted using smallmolecule drugs. A popular target of these drugs is the DNA binding site on the TF along with
the DNA sequence that the TF binds to. Disrupting a cancerous TF's ability to associate with
DNA will stop it from wreaking havoc on the organism. Most TFs are also regulated by small
molecules called cofactors which have unique binding sites on their respective TFs. This spot
also presents a potential target for drugs as many TFs cannot function without their cofactors
bound. In this review, studies on disrupting TF-DNA interactions and TF-cofactor
interactions with hopes of treating cancer will be discussed.
Biological Role of Transcription Factors
The human genome is massive, and most of
it (~99%) is never used to create proteins.1 In
order for life to work, proteins called
transcription factors (TFs) do the job of sifting
through the genome and allowing for the
proper genes to be expressed to the correct
extent. TFs can be activators or repressors of
specific genes. Throughout one's life, the
expressed genes change based on one’s
developmental stage, diet, and even exposure
to UV light.2,3,4 Without TFs, the human body
would not be able to carry out biological
functions properly or respond to stress from
the environment. While TFs do play vital roles
in the body, it is not uncommon for their
function to become altered in a way that leads
to the onset of diseases such as cancer. Due to
significant improvements in cancer research, it
is becoming more feasible to design specific
molecules that can interact with the cancerous
TFs to treat the disease.
TFs perform their duties by chemically
interacting with DNA at a specific target
sequence or binding to other proteins that are
already interacting with DNA. The interactions
between TFs and DNA can be broken down into
a few categories that include most of the

observations that have been made: helix-turnhelix, zinc fingers, and leucine zippers.5 All of
these protein shapes generally interact with
the major groove of DNA (Fig. 1), which is the
double helix's open side. The major driving
forces for these chemical reactions are
hydrophobic interactions, hydrogen bonds,
and ionic bonding between the protein and
DNA sequence.6 When the DNA and proteins
interact, energy is stabilized due to less
hydrophobic surfaces being exposed to water
(the hydrophobic effect). Charged residues on
the protein can also orient to ionically bond to
oppositely charged atoms on the DNA
molecule.
How Transcription Factors Become Cancerous
TFs are evolved to bind specific sequences
by interacting with the nucleotides in the DNA
double helix. They must be highly specific, so
they influence the correct gene. Suppose a
critical amino acid is replaced in the TFs
binding site or a nucleotide in the recognition
sequence of DNA is changed. In that case, there
is a high chance that the binding will be
affected, and the cell/organism’s physiology
could be compromised. The real issue is when
these genes are associated with the cell cycle or
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Figure 1: Structure of DNA Double Helix7
Major grooves are around 36 angstroms (3.6 nm)
apart, which has caused TFs to evolve their
geometries accordingly to bind to multiple major
grooves at once when interacting with DNA. The
minor groove is not targeted by TFs nearly as often
due to steric hindrance.

the cell's quality control system. Tumor
suppressing genes are the primary type of
defense cells have against mutations and
cancer, so when they are mutated or underexpressed, DNA mutations can occur easily.8
For example, if a tumor suppressor gene's
promoter (where the TF binds to DNA
sequence) acquires a mutation and the TF
cannot allow for the gene’s expression, then a
tumor will be able to grow more rapidly.
Down-regulating tumor suppressor genes
is a direct cause of cancer, but for cancer to
occur, there is also the need to upregulate
genes that lead to cell division, such as cyclins9
and epidermal growth factors.10 These genes
are considered proto-oncogenes because they
can cause cancer if they acquire the correct
mutation. There are several ways a protooncogene can become overactive from a
mutation. A different TF may recognize the
new promoter sequence and begin expressing
this gene when it should not. There is also the
chance that a mutation causes a gene's normal
TF to bind even tighter to the promoter, which
would also lead to overexpression because the
˒˔

TF would not be able to detach after a cell
division. Some additional classes of genes that
are
commonly
involved
with
cancer
development are angiogenesis (blood vessel
forming) genes and metastasis genes that
allow cancer to spread to different organs
through the bloodstream.
When a cancerous mutation happens inside
a single cell, the defense mechanism is
generally a tumor suppressor gene called p53
that recognizes the mistake and induces
apoptosis (cell suicide). This stops the cell
replication process. Many cancers are due to a
combination of mutations, and p53 being
mutated is extremely common in cancer
because it renders the cells defenseless against
the mad proliferation and growth of a tumor.11
When p53 is defective and cannot recognize
genetic
mistakes,
these
errors
begin
accumulating in the cancerous cells. This
allows for the disease to reach the fourth stage
and ultimately spread throughout an organism.
Targeting Cancerous Transcription Factors
with Drugs
TFs are heavily regulated inside a cell due to
the power they possess. Some of the most
common methods of regulation include
cofactor
binding
and
phosphorylation/
dephosphorylation. Cofactors are non-protein
chemical molecules that bind to a site on an
enzyme or protein (such as a TF) and change
its function. Phosphorylation of a protein alters
its shape because the only three amino acids
that can be phosphorylated are serine,
threonine, and tyrosine. All three are noncharged amino acids with a hydroxyl group
that the negatively charged phosphate is
attached to, which alters the protein's
electronic forces in a way that can activate or
repress its activity. Both cofactor binding sites
and amino acids in phosphorylation sites are
potential targets for drugs to interact with,
along with the more obvious DNA binding
motif of the TF and the actual DNA recognition
sequence that the TF binds to.
The extreme specificity of binding sites
makes creating a drug to block a TF difficult,
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and the success rate is low. However, now that
protein imaging and protein folding are better
understood, the development of these drugs is
becoming more of a possibility. Most cancers
are dependent upon TFs not functioning
correctly, which leads to uncontrolled cell
growth and proliferation.12 Designing a drug
that fits precisely in the binding pocket of a TF
without altering any other physiological
process can be challenging, but if successful,
this could be the future of cancer treatment.
One of the best things about this form of cancer
treatment is it will be exponentially less
destructive to healthy cells when compared to
the other forms of cancer treatment that are
prevalent today, such as radiation and
chemotherapy. A downside to this type of
treatment is that each TF that is associated
with causing cancer will need to have its own
drug developed because they are chemically
different. So, focusing on the most common
TFs involved with cancer will provide the most
benefit to society without being too
uneconomical in the research process. In this
review, some of the most common cancerous
TF mutations will be discussed in detail, along
with attempts to create drugs that interfere
with these mutated TFs.

assay. A molecule (AI-10-49) was found and
tested to show it could prevent the formation of
the CBFϠ-SMMHC to restore the normal
function of RUNX1 (Fig. 2). The drug was
deemed successful as it delayed the onset of
leukemia in mice significantly. Furthermore,
they used nuclear magnetic resonance (NMR)
to show that the molecule (AI-10-49) binds to
tryptophan and a tyrosine amino acid on the
CBFϠ-SMMHC
complex
to
prevent
its
association with RUNX1. If it is possible to
employ this technique to find inhibitors for
other improperly functioning TFs, that should
be pushed for in the future.
The estrogen receptor (ER) is commonly
studied due to its implications in breast cancer.
Shiau et al. worked with the drug tamoxifen
and its derivatives which are molecules that
interrupt the binding site of estrogen, which is
on hERϟ.14 In many instances, there is an
overexpression of ERs in breast cancer cells
which leads to hypersensitivity toward a typical
concentration of estrogen. This pathway
results in rapid cell division. Developing a drug
to block the estrogen binding site was of
utmost importance due to its direct implication

Interrupting Protein-Protein Interactions to
Treat Cancer
Many studies have attempted to disable the
interactions between TFs and their cofactors by
designing a molecule that will fit directly into
this site or alter the site covalently.13,14,15 The
association of CBFϠ-SMMHC with the TF
RUNX1 has cancerous implications, and a
potential treatment has been found.13 RUNX1 is
a TF that normally only binds CBFϠ as a
cofactor. However, chromosomal mutation
results in CBFϠ and SMMHC complexing and
binding RUNX1, which downregulates the TF
compared to its regular activity. This results in
the onset of acute myeloid leukemia. Previous
studies scanned the NIH database for a
molecule that could inhibit the association of
CBFϠ-SMMHC with the TF RUNX1 using a
fluorescence resonance energy transfer (FRET)

Figure 2: Concentration of the CBFϠ-SMMHC
Complex
This bar graph shows that after the drug AI-10-49
was applied, the concentration of the CBFϠSMMHC complex decreased while the amount of
free RUNX1 increased.13 This should allow for
RUNX1 to resume its normal transcriptional
activities.
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in several types of breast cancer. X-ray protein
crystallography was performed on the ligandbinding domain (LBD) of hERϟ when it was
bound to DES (synthetic estrogen). It was
found that the drug 4-hydroxytamoxifen was
also bound to the same site but in a different
orientation.14 Fig. 3 below shows the two
molecules and compares their interactions with
the hERϟ receptor’s LBD. The molecules appear
different, but the main forces for interaction in
this receptor are hydrophobic interactions
(shown in green). However, both molecules
have hydrogen bonds between an -OH group
and arginine residue 394 on the ER (shown in
red). DES has an additional hydrogen bond with
glutamate 353. Using X-ray crystallography to
decipher the LBD of TFs is a helpful technique
that will give us powerful insight into the types
of molecules and functional groups that need to
be on the drugs being designed as inhibitors.
CDK7 (Cyclin-Dependent Kinase 7) is a
common protein that can become faulty in
blood cancers and is directly involved with the
cell division process. This enzyme is part of a
TF complex (TFIIH) and activates many other
proteins that aid in cell division through
phosphorylation. So, when TFIIH becomes

Figure 4: CDK7 Mutation
This illustrates the mutation in CDK7 that rendered
THZ1 ineffective. The mutation was subtle enough
for CDK7 to remain functional, but the S atom must
be present for THZ1 to bind.

overactive, the consequences are dire. A
successful study has been published showing
that a molecule (THZ1) can covalently bind to a
non-active site of CDK7 and inhibit its activity
thus causing specific cancer cell lines to stop
proliferating.15 The binding of this drug must
have some allosteric effects on CDK7 as it was
shown through mass spectroscopy that the
molecule binds to a remote cysteine amino acid
on the enzyme. To further support this point,
the proposed binding site of THZ1 was mutated
from cysteine to serine on CDK1, and the
molecule could not bind or inhibit the
proliferation of the cancer cell lines.15 Using
subtle mutations to show how a drug interacts
with its target protein is a great strategy,
especially if the mutation does not alter the
chemistry enough to disrupt the normal
protein function, such as in this case (Fig. 4).
Interrupting Protein-DNA Interactions to
Treat Cancer

Figure 3: Synthetic Estrogen (DES) and Its
Competitive Inhibitor (4-Hydroxytamoxifen)
The green atoms are participating in hydrophobic
interactions with non-polar amino acids in the
hERϟ ligand-binding domain. The red atoms are
hydrogen bonding with Arg394 and Glu353; both
hydroxyl groups of DES are highlighted because
they are symmetrical and can orient either way in
the binding pocket.
˒˖

Interfering with an active TFs function is as
effective as blocking the TF activation
altogether. This is why many studies have been
done with intentions of hindering the TF's
ability to recognize and bind to its specific
sequence of DNA.16,17,19 Flavopiridol has been
extensively studied as it was shown to kill
cancer cells in culture, so the mechanism
behind its ability needs to be elucidated.16
Using DNA cellulose affinity chromatography,
it has been shown that Flavopiridol binds to a
DNA sequence that prohibits the binding of
STAT3; STAT3 is a TF involved in many
different cancers, and it is a crucial gene to
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Figure 5: Expression of STAT3 Induced Genes
This chart shows the different drugs tested to
reduce the expression of STAT3 induced genes.16
Flavopiridol was the only one successful at
significantly reducing STAT3 activity.

allow cancer to spread and new blood vessels to
form.18 To further prove this point, the
expression level of the genes that STAT3
induces was evaluated, and it was found that
the induced genes were all expressed less when
the cells were treated with Flavopiridol
(Fig. 5).16
AP-1 is a gene involved with metastasis (the
ability of cancer to spread) and tumor
suppression involved with highly aggressive
breast cancer.20 Breast cancer can spread to
other vital organs such as the lungs and brains
easier than most other types of cancer. NMR
was used to show that MLN944 was directly
interacting
with
the
DNA
sequence
(ATGCAT)2.17 Even further, electrophoretic
mobility shift assay (EMSA) was utilized to
show that MLN944 was binding to a sequence
that was inhibiting the binding of AP-1, which
is a TF involved with metastasis and tumor

suppression. They found that MLN944 lays flat
through the DNA sequence's major groove.
Additionally, one phenazine ring of the
molecule (Fig. 6) anchors down between the
thymine and guanine while the other ring goes
between the cytosine and adenine nucleotides.
When designing a molecule that is meant to
bind to DNA, adopting a symmetrical form
around the length of the gap between adjacent
major grooves may be a great option. Many
natural biological molecules that bind DNA
have evolved this geometry; learning from this
and designing symmetric DNA binding drugs
should improve success.
HIF-1 is a TF that allows for angiogenesis to
occur when the tumor environment becomes
hypoxic (low oxygen). Therefore, it is crucial
that cancer cells produce new blood vessels to
acquire nutrients. A study has been conducted
that identified a compound (echinomycin) able
to bind directly to the DNA sequence HIF-1
binds to when activated.19 EMSA was used to
show that the drug did indeed bind the correct
sequence of DNA. The main gene that HIF-1
increases the transcription of in tumors is
vascular endothelial growth factor (VEGF). It
was shown that echinomycin inhibited the
expression of this gene in a dose-dependent
manner (Fig. 7). The unique thing about HIF-1
is that it does not need to be mutated to help
cancer. It is automatically activated in the cell
when oxygen levels drop, and oxygen levels
plummet when tumors start to form with no
blood vessels to provide them with O2. That
makes this study applicable to all solid tumors
which use angiogenesis to secure nutrients
from the host and grow.

Figure 6: Structure of the Anticancer Drug MLN944 10
This molecule has a substantial positive charge (shown in red) that aids in its ability to anchor tightly to DNA
which is negative because of its phosphate backbone. This molecule's symmetrical nature also helps
strengthen the interaction due to the DNA double helix being antiparallel in sequence.
˒˗
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Figure 7: Echinomycin Concentrations and VEGF
Transcription
This graph shows how different concentrations of
echinomycin influence the transcription of VEGF.19
Echinomycin blocks HIF-1 activity strongly in
hypoxic conditions, which are common in tumor
cells but not in normal cells.

Conclusions
Many
laboratories
worldwide
have
overcome a once impossible feat of designing
drugs to inhibit the cancerous activities of
deregulated TFs. Inventive strategies have been
devised to find potential drugs for specific
binding sites of TFs along with methods that
help confirm the drug is doing its intended job.
Applying fluorescence resonance energy
transfer (FRET) is one strategy that allows for
thousands of potential drugs treatments to be
explored.13 In addition to FRET, electrophoretic
mobility shift assay (EMSA) is an excellent
method to show that the designed drug
successfully binds the correct sequence of DNA.
EMSA can also be used to show that the drug is
inhibiting the TF of interest from binding to its
target DNA sequence. After confirming that the
drug indeed binds with the TF, mutating key
residues involved with this interaction is a
method to obtain even more detail of the
binding mechanism. Finally, one of the most
appropriate ways to test these drugs’ abilities
against cancer is to compare the expression
levels of the TF’s target genes before and after
administering the drug to see if there is any
influence. If the levels of proliferation genes
are dropping with the drug dosem then one can
conclude the treatment is working.
In today’s society, the dominant forms of
˒˘

cancer
treatment
are
radiation
and
chemotherapy. Both of these treatments have
extreme side effects. They can increase the
chances of the patient developing a second type
of cancer in the future by causing many
mutations.21 The side effects of inhibiting
cancerous TFs are not as harmful as radiation
and chemotherapy side effects. However, it
should be noted that not many human trials
have been done with these drugs, so the effects
are not completely known. In the future, more
TF-DNA interactions should be targeted
utilizing symmetrical molecules that have DNA
interaction sites ~3.6 nm apart. This allows the
molecule to avoid steric hindrance and bind to
the major groove of DNA in attempts to block
TF binding. The methods reviewed in this
paper could outcompete the current forms of
cancer treatment if the experiments associated
with them continue to succeed as they have
been.
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